Kornimate/medical-research-clean huggingface dataset:
whole blood biospecimen collection for subjects with chronic granulomatous disease (cgd)

Conditions: Chronic Granulomatous Disease

Summary: the primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with chronic granulomatous disease (cgd). the biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. the disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.


Eligibility criteria:
inclusion criteria: * the participant is willing and able to provide written informed consent * the participant is willing and able to provide appropriate photo identification * participants aged 18 to 85 * participants have been diagnosed with chronic granulomatous disease (cgd) * subjects who have a confirmed p47phox cgd mutation or subjects who have a confirmed x-linked cgd mutation exclusion criteria: * participants who are pregnant or are nursing * participants with a known history of hiv, hepatitis, or other infectious diseases * participants who have taken an investigational product in the last 30 days * participants who have experienced excess blood loss, including blood donation, defined as 250 ml in the last month or 500 ml in the previous two months
nebulized rns60 for the treatment of amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to determine whether nebulized rns60 is effective in the treatment of amyotrophic lateral sclerosis (als).


Eligibility criteria:
inclusion criteria: * probable, probable-laboratory supported, or definite als, either sporadic or familial according to modified el escorial criteria * disease duration \< 3 years * age 18 to 80 * able to provide informed consent and to comply with study procedures * subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study) * women must not be lactating or able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control) for the duration of the study, and for 3 months after study completion * men should practice contraception for the duration of the study and for 3 months after completion exclusion criteria: * diagnosis of a motor neuron disease other than als (e.g., primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy) * clinically significant unstable medical condition (other than als) that would pose a risk to the participant if they were to participate in the study or that would impact survival or functional disability in the next 12 months * abnormal liver function defined as aspartate aminotransferase (ast) and/or alanine aminotransferase (alt) \> 3 times the upper limit of the normal * renal insufficiency (glomerular filtration rate \< 60) * active pulmonary disease * prior poor compliance with an inhalation device * the presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to judgment by the principal investigator. * history of human immunodeficiency virus (hiv) infection, clinically significant chronic hepatitis, or other active infection. * active participation in another als clinical trial within 30 days of the screening visit * other experimental treatments or anti-inflammatory/immunomodulatory medications used in the preceding 3 months
clinical pregnancy rate after removal of unsuspected polyps

Conditions: Infertility

Summary: polyps are fleshy outgrowths of the inner lining of the womb which may hinder implantation of embryo and lead to subfertility.this study evaluates whether removal of endometrial polyps in womb affects chances of pregnancy in women in whom no other causes of subfertility can be found. half of the women would have these polyps removed after their consent and the other half who would not consent would not undergo any such intervention


Eligibility criteria:
inclusion criteria: * normal semen analysis * 24 months of unprotected sexual intercourse * normal tvs * normal hysterosalpingogram * evidence of spontaneous ovulation * no history of pelvic inflammatory disease * polyps on saline sonography exclusion criteria: * history of taking hormones * thyroid disorder * prior hysteroscopy treatment * intermenstrual blood loss.

Keywords: polyps saline sonography infertility
in situ simulation training in lifeguard organisations

Conditions: Drowning; Drowning, Near; Drowning and Nonfatal Submersion; Drowning/Submersion; Drowning and Submersion While in Natural Water

Summary: this retrospective study will analyse a dataset consisting of 919 in situ simulation assessments collected between 2018 and 2023 in a danish nationwide surf lifeguard organisation. the primary objective is to estimate the pass/fail ratio of in situ simulation assessments. the secondary objective is to analyse risk factors associated with a failed assessment. these results may guide future efforts to improve the danish surf lifeguard training program.

background: once weekly on all lifeguard-supervised beaches during the summer holiday period, a lifeguard instructor sneaks undetected into the primary surveillance zone between the flags and raises a hand to indicate a drowning scenario. this is called in situ simulation and is used to assess danish surf lifeguards' rescue and medical skills. it is an unannounced test occurring during working hours, followed by feedback and training with the lifeguard instructors. previous data indicate that approximately 1 in 5 lifeguards fail the in situ assessment. analysing data from in situ simulation assessments may pinpoint areas for future improvement. objectives: the primary objective is to estimate the pass/fail ratio of in situ simulation assessments. the secondary objective is to analyse risk factors associated with a failed assessment. these results may guide future efforts to improve the danish surf lifeguard training program. methods: this retrospective study will analyse a dataset consisting of 919 in situ simulation assessments collected between 2018 and 2023 in a danish nationwide surf lifeguard organisation. data on the local conditions (e.g., wave height, time of the day, and the number of beach visitors) and the in situ evaluation (pass/fail) were extracted directly from the predefined variables. data on failure reasons were extracted through manual validation of the semi-structured free text fields by four independent observers. any discrepancies were resolved by a senior member of the research group.

Eligibility criteria:
inclusion criteria: * all in situ assessments in the nationwide danish lifeguard organisation from 2018 to 2023. exclusion criteria: * blank entries * dublets

Keywords: in situ simulation simulation drowning lifeguard lifesaver
a study to evaluate the safety, immunogenicity, and pharmacokinetics of gr2102 in healthy adult

Conditions: Respiratory Syncytial Virus Infections

Summary: the goal this clinical trail is to evaluate the safety、pharmacokinetic and immunogenicity of gr2102 injection。 subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either gr2102 injection or placebo administration, with each subjects will be enrolled in only one of these groups。

this is a randomized, double-blind, placebo-controlled, single-dose administration study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic profile of gr2102 injection in healthy adult chinese subjects. after signing the informed consent form, subjects who meet the criteria for enrollment will be entered into different groups according to the randomization number.subjects will be enrolled in only one of these groups. only after the 8 subjects in the current group have completed at least 7 days of safety and tolerability observations and have been determined to be safe and tolerable, will another group of subjects be allowed to proceed to the next group . after completion of dosing, follow-up will be at least 150 days.

Eligibility criteria:
inclusion criteria: 1. healthy adult subjects 2. signed informed consent exclusion criteria: 1. signs and symptoms of upper respiratory tract infection prior to randomization 2. prior use of rsv vaccine or rsv antibody-based medications 3. history of malignant tumor

Keywords: respiratory syncytial virus rsv respiratory infection
maris study; mediterranean approach to reduce insulin-resistance study

Conditions: Insulin Resistance; Metabolic Syndrome X; Dyslipidemia; Hypertension; Overweight

Summary: background: during the 1990s, the prevalence of the metabolic syndrome in the netherlands ranged from 3% in women of 20-39 yrs to at least 33% in men 55 yrs and older and it is expected to increasing. prevention is therefore warranted. in this respect the amount and type of fat in the diet deserves attention. recently, an intervention study reported that a diet high in mono-unsaturated fatty acids (mufa) such as from olive oil, increased insulin sensitivity in healthy subjects. however, additional beneficial effects can be expected from the mediterranean diet as a whole. hypothesis: replacing saturated fatty acids (sfa) by mono-unsaturated fatty acids (mufa) will improve hyperinsulinemia and dyslipidemia, and a typical mediterranean diet will even have more pronounced effects. study objectives: to investigate the impact of the mediterranean diet, and especially the intake of mufa, on markers of the metabolic syndrome in high-risk subjects. methods: the controlled dietary intervention will include 60 subjects aged 40-65 years with moderate abdominal obesity. after a run-in diet for 2 weeks they will be assigned randomly to receive one of the three diets for a period of 8 weeks. measurements of serum insulin concentration and other parameters will be carried out at weeks 2 and 10. expected results: our study will provide information on the role of mufa and the expected beneficial impact of other factors of the mediterranean type of diet on the metabolic syndrome.


Eligibility criteria:
inclusion criteria: * waist circumference ≥ 94 cm for men or ≥ 80 cm for women * age from 40 to 65 years at the time of randomisation * written informed consent obtained exclusion criteria: * unable or unwilling to comply with study procedures. * the use of drugs for lowering serum cholesterol, serum triglycerides, blood pressure, or diabetes. * unusual dietary patterns, including high alcohol intakes * recent (\< 4 weeks) or current participation in a study with any investigational drug or dietary intervention. * high concentrations of total cholesterol (\>8 mmol/l). * diabetes mellitus. * being pregnant or giving breastfeeding.

Keywords: mufa mediterranean diet insulin resistance metabolic syndrome x
effects of mckenzie exercises with and without mulligan mobilization in text neck syndrome.

Conditions: Neck Syndrome; Forward Head Posture

Summary: this study aims to determine the effect of mckenzie exercises with and without sustained natural apophyseal glide on pain, disability, and craniocervical angle in adults with text neck syndrome.

text neck syndrome is a condition that results from the repetitive use of electronic devices, causing the neck to flex forward or down for extended periods. this can lead to symptoms such as neck pain, reduced range of motion, weakened muscles, altered joint position, and postural changes such as forward head posture and rounded shoulders. in this randomized clinical trial, forty eight participants with text neck syndrome will be randomly assigned to one of the two intervention groups: group a :mckenzie exercises without mulligan mobilization and group b:mckenzie exercises with mulligan mobilization . randomization will be performed using a convenient random sampling method via sealed opaque envelopes. each participant will receive a total of eight treatment sessions over a four-week period. the efficacy of the interventions will be assessed at the beginning (first session), conclusion (eight session). outcome measures, including pain intensity, disability levels and craniocervical angle will be evaluated using the numeric pain rating scale (nprs), neck disability index (ndi) and image j software, respectively. data will be analyzed using spss software version 26. normality of data will be assessed using the kolmogorov smirnov test. for within-group comparisons, either repeated measures anova or the friedman test will be used. to compare changes between the groups, the independent t-test or mann-whitney u test will be applied, depending on the data distribution. the analysis of these outcome measures will provide valuable insights into the impact of the interventions on participants' symptoms and postural alignment.

Eligibility criteria:
inclusion criteria: age (18-35 years) male and female cva \ 88 exclusion criteria: neck surgery spinal infection or inflammatory disorder diagnosed cases of disc prolapse, stenosis, herniation, spondylolisthesis and osteoporosis, torticollis, scoliosis.

Keywords: text neck syndrome mckenzie exercises sustained natural apophyseal glide neck pain
safety/efficacy of avp-923 in the treatment of emotional lability (uncontrolled crying & laughing) in patients with als

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to compare and evaluate the safety of avp-923 (dextromethorphan/quinidine) for the treatment of emotional lability in als patients.


Eligibility criteria:
inclusion: * 18 to 80 years of age, inclusive * confirmed diagnosis of als or probable als * clinical history of pseudobulbar affect * if female, must not be pregnant, breast-feeding, or planning a pregnancy during the course of the study, and must have a negative urine pregnancy test prior to start of study * if female, must have been practicing an established method of birth control for at least the prior month (oral contraceptive tablets, hormonal implant device, intrauterine device, diaphragm and contraceptive cream or foam, condom with spermicide, tubal ligation, or abstinence) or be surgically sterile or post-menopausal * must be willing to not take any prohibited medications during participation in the study exclusion: * known sensitivity to quinidine or opiate drugs (codeine, etc.) * on any anti-depressive medication * recently (within two months) diagnosed with als * currently participating in, or who within the past 30 days have participated in, the study of another investigational new drug * previously received treatment with co-administration of dextromethorphan and quinidine * history of substance abuse within the past two years * women who are pregnant or likely to become pregnant during the course of the study

Keywords: avp-923 dextromethorphan quinidine pseudobulbar affect
assessment of different scores in predicting outcome in aecopd patients in emergency department

Conditions: Chronic Obstructive Pulmonary Disease

Summary: evaluate the value of different scores in predicting hospital mortality and need for mv in patients presented to ed with aecopd.

chronic obstructive pulmonary disease (copd) is one of the top three causes of death worldwide, and 90% of deaths occur in low- and middle-income countries. acute exacerbation of chronic obstructive pulmonary disease(aecopd) is defined as an acute change in patient's dyspnea, cough, or sputum beyond normal variability that is sufficient to warrant a change in therapy. aecopd has a negative effect on the quality of life, admission and readmission rates, and disease progression. for these reasons, appropriate management of acute exacerbations is recommended by national and international organizations. identifying high-risk dying patients on hospital admission helps in triaging them to the required level of care. the use of early warning scores in follow-up is recommended for the early detection of critically ill patients and the prediction of clinical deterioration. curb65, bap65, qsofa , decaf and news, which mainly involve mental status, respiratory rate, oxygen saturations, pulse, blood pressure, age, bun level, etc., can be used to predict aecopd-associated mortality in ed given the simple structure and data availability.

Eligibility criteria:
inclusion criteria: * all patient presented to ed with acute exacerbation of copd. exclusion criteria: * patient presented with acute insult affecting other system. * patient transferred to other centers. * inadequate data.
desmopressin melt therapy in nocturnal polyuria patients: pharmacodynamic study

Conditions: Nocturia

Summary: the objective of this study is to find out what the pharmacodynamic (pd) characteristics of desmopressin melt are in nocturia patients (compared to healthy volunteers and children). the main questions the investigators want to answer are: * are differences related to the pathophysiological factors involved in nocturia? * are there age/gender/size differences? * can the investigators identify patients who are likely to develop hyponatraemia? * can the investigators individualize treatment and reduce risk for hyponatraemia? the patient will be given a prescription to buy minirin melt 60µg at the local pharmacy. during 30 days, the patient has to take minirin melt 60µg in the evening before going to bed. there are two groups of patients: group a: patients that still have to undergo an evaluation phase, according to standard procedures (e.g. osmolality test, blood sample). this procedure is not a part of this study. the study starts when the 1st minirin melt tablet has been taken (= day 1). group b: this group already went through the evaluation phase (by participation to study 1 or study 3 as mentioned above) and they have been prescribed minirin melt 60 µg ambulatory. the study starts when the patients takes his first prescribed minirin melt tablet: * on day 3 and day 7 a blood sample will be taken at the uz ghent for safety control (na+, k+, creatinin, osmolality = good clinical practice guideline). these first 2 visits (day 3 and day 7) are standard procedure. if the patient is at high risk for side effects, blood has to be taken during the first 7 days. * on day 3 the patient has to give a urine sample. * patients have to fill out a frequency/volume chart during the first 14 days. * on day 30, a 3rd blood sample will be taken


Eligibility criteria:
inclusion criteria: * written informed consent prior to the performance of any study-related activity * patients, men and women, 18 years and older, with an average of ≥ 2 nocturnal voids per night * evidence for nocturnal polyuria (nocturnal urine volume \>33% of total volume over 24h), determined on frequency/volume chart * diuresis \<2.5l exclusion criteria: * hypersensitivity/anaphylactic reaction on desmopressin or one of the other substances * pregnancy * genitourinary tract pathology (infection, tumor,...) * urolithiasis * suspicion or evidence of cardiac failure * moderate to severe renal insufficiency (creatinin clearance \< 60 ml/min) * psychogenic or habitual polydipsia * hyponatraemia or predisposition for hyponatraemia * diabetes insipidus * syndrome of inadequate adh production * suspicion or evidence of liver failure

Keywords: nocturnal polyuria
therapeutic exercise program of physiotherapy using telerehabilitation on chronic phase stroke patients

Conditions: Stroke

Summary: stroke is the main cause of physical disability in adults in catalonia. despite this, there is a lack of evidence on physiotherapy interventions during the chronic phase of the pathology. the objective of the study is evaluate the effectiveness of a therapeutic exercise program of physiotherapy through the use of telerehabilitation on functional capacity in activities of daily living in patients with stroke in chronic phase. for this purpose, the investigator conduct a multicenter randomized controlled clinical trial. a minimum of 75 participants will be recruited in three intervention groups (n=25 each group) from primary care centers of the institut català de la salut. the sample will be made up of people over 18 years of age with a medical diagnosis of stroke, in a chronic phase and with physical sequelae. research team will evaluate as the main variable the functional capacity for the management of activities of daily living (barthel index); as well as sociodemographic variables. also secondary variables such as motor function (mmas), muscle tone of affected limbs (mas), muscle strength of affected limbs (mrc), balance (pass), gait efficiency (wgs, 4mwt), perception of musculoskeletal pain (bpi), perception of fatigue (fss), risk of falls (tug), perception of quality of life (newsqol), and perception of quality of life (newsqol), and perception of perceived subjective change after treatment (groc). the variables will be collected, before and after the intervention , which will consist of 30 sessions (3 sessions/10 weeks). the analysis will be using a mixed linear model (anova 3x3). significance level p\<0.05.


Eligibility criteria:
inclusion criteria: * age 18 years or older * medical diagnosis of stroke * stroke condition present for more than 6 months * physical sequelae secondary to stroke * minimum score of 1 on the medical research council scale for overall muscle strength of affected limbs * maximum score of 3 on the modified ashworth scale for overall muscle tone of affected limbs * maximum score of 4 on the modified rankin scale for disability * access to computer equipment (tablet, desktop or laptop computer, or smartphone) exclusion criteria: * undergoing other non-pharmacological physical treatments for stroke sequelae improvement and/or maintenance * previous decreased motor functional capacity with a barthel scale score of less than 60 points * cognitive and/or language barriers that hinder the understanding of informed consent and intervention * participation in another clinical trial during the study period that may impact the results of the variables to be evaluated

Keywords: chronic disease primary care therapeutic exercises telerehabilitation